ReportsnReports . com adds new research report Global Tuberculosis Drug Market 2017-2021 . This report covers the present scenario and the growth prospects of the global tuberculosis drug market for 2017-2021 . To calculate the market size , the report considers the volume and services .
Inquire for more information at http :// www . reportsnreports . com / contacts / inquirybeforebuy . aspx ? name = 917332
The following companies are the key players in the global tuberculosis drug market : Lupin , Otsuka Novel Products , Pfizer , Sandoz , and Sanofi . Other prominent vendors in the market are : AstraZeneca , Archivel Farma , bioMérieux , Cepheid , EIKEN CHEMICAL , and Epistem .
Global Tuberculosis Drug Market 2017-2021 , has been prepared based on an in-depth market analysis with inputs from industry experts . This report covers the market landscape and its growth prospects over the coming years . The report also includes a discussion of the key vendors operating in this market .
Purchase directly at http :// www . reportsnreports . com / purchase . aspx ? name = 917332
Tuberculosis ( TB ) is caused by Mycobacterium tuberculosis and often affects the lungs . It spreads from person to person through the air in the form of a cough , sneeze or spit . TB affects adults more when compared with children . The analysts forecast global tuberculosis drug market to grow at a CAGR of 3.17 % during the period 2017-2021 .
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry . The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors .
Inquire for discount at http :// www . reportsnreports . com / contacts / discount . aspx ? name = 917332
The latest trend gaining momentum in the market is focus on development of shorter TB drug regimens . MDR-TB needs a treatment course of second-line drugs over 18 months or more , which is quite higher than the standard six months of treatment with first-line TB drugs . Since last 5-7 years , the R & D efforts have been accelerated to reduce this elongated timeline and conventional treatment regimen for MDR-TB .
According to the report , one of the major drivers for this market is increase in outbreak of TB-HIV coinfections . The risk of developing TB is 26-32 times greater in people living with HIV than among those without HIV . HIV and TB are inter-related co-infection where one could lead to another . It is very prominent to find individuals with HIV infection along with either latent or active TB disease .
Further , the report states that one of the major factors hindering the growth of this market is insufficient demand and high drug cost in developed countries . The potential of the market has reduced considerably because of the decline in the number of TB cases in developed countries . New TB cases are occurring only in developing countries . However , pharmaceutical companies presume that only a few individuals in developing countries can afford TB drugs . Moreover , the existing healthcare budgets and policies in developing countries are not quite attractive enough to lure the big pharmaceutical companies .
About Us :